TO STUDY THE RELATION OF ALKALINE PHOSPHATASE ENZYME ACTIVITY IN GINGIVAL CREVICULAR FUILD WITH THE RATE OF TOOTH MOVEMENT FASTENED BY PLATELET RICH PLASMA INJECTION

Completed

Conditions: Other specified disorders of teethand supporting structures,

Registration Number: CTRI/2021/09/036459

Lead Sponsor: DR BHARAT KRISHNAN C K

Brief Summary: Fixed orthodontic therapy requires longer duration of treatment, usually about 2-3 years, accompanied by great concerns and risks such as caries, external root resorption and decreased patient compliance. To shorten the duration of treatment time, the concept of accelerated orthodontic tooth movement was introduced. One of the recently introduced agent to locally accelerate the orthodontic tooth movement is Platelet Rich Plasma (PRP). PRP is an autologous concentration of platelets in a small volume of plasma, rich in various growth factors and cytokines which potentiates the ability to stimulate the osteoblastic and osteoclastic activities and can have possible effect on orthodontic tooth movement. Alkaline Phosphatase (ALP) is an enzyme that is secreted during bone formation reflecting the osteoblastic activity. Estimation of ALP may possibly be an indicator of the bone remodelling and therefore an indicator for rate of tooth movement following force application.

This study aims to evaluate the effects of local administration of PRP on the rate of tooth movement by comparison of the ALP levels at the experimental vs control sites and moving unit vs anchoring unit.

The patients will be subjected to experiment based on randomly assigned split mouth design to prevent individual biologic variation. Pre-adjusted edgewise MBT prescription bracket system will be used with 0.022 slot and anchorage reinforcement by auxiliaries like Transpalatal arch and lingual arch or 2nd molar banding will be decided. After levelling and aligning, during the retraction phase, GCF samples will be collected using microcapillary tubes from the experimental site canine and molar and the control site canine to evaluate the baseline levels of ALP. Following this the pharmacological agent platelet rich plasma will be administered in the experimental site canine and GCF samples will be collected at 14 days,21st day and 3rd month post administration to evaluate for ALP levels

Detailed Description: Not available

Recruitment & Eligibility

Status: Completed

Sex: All

Target Recruitment: 10

Inclusion Criteria

class I bimaxillary malocclusion needing all first premolar extractions.

Exclusion Criteria

Patients under any other medication which affects tooth movement Patients with craniofacial anomalies Patients with periodontal disease Patients with any kind of systemic disease that affects tooth movement.

Study & Design

Study Type: Interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The level of ALP in the GCF of experimental side canine and molar and control side canine is evaluated.	The GCF samples from the experimental canine and molar and control canine will be evaluated for the ALP levels using Human ALP ELISA test kit at T0(baseline), T1(21st day), T2(3rd month).

Secondary Outcome Measures

Name	Time	Method
1.The rate and amount of tooth movement in Platelet rich plasma administered side and non administered side	2.The anchorage loss on the experiment and non experiment side.

Trial Locations

Locations (1): FACULTY OF DENTAL SCINECES, RAMAIAH UNIVERSITY OF APPLIED SCIENCES
🇮🇳
Bangalore, KARNATAKA, India
FACULTY OF DENTAL SCINECES, RAMAIAH UNIVERSITY OF APPLIED SCIENCES
🇮🇳Bangalore, KARNATAKA, India
Dr BHARAT KRISHNAN C K
Principal investigator
9945475074
bharatckrishnan@gmail.com